This 2024 review article explores the role of low-dose colchicine (0.5 mg daily) as an anti-inflammatory therapy in reducing adverse cardiovascular events following acute coronary syndrome (ACS). Colchicine exerts its effects by inhibiting microtubule polymerization, thereby reducing leukocyte activation and inflammatory responses implicated in atherosclerotic plaque destabilization. Clinical trials, including
